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Abstract The N terminus of myosin light chain 1 (MLC-1) of 
skeletal muscle bind to the C terminus of actin. We investigated 
whether the N termini of human cardiac MLC-1 isoforms 
likewise bind to actin. Furthermore, we investigated whether the 
N-terminal sequence 5-15 (P5-14) of MLC-1 of human atrium 
(ALC-1) and ventricle (VLC-1) bind with different affinities to 
actin. Affinity beads were produced by covalently coupling a 
synthetic peptide corresponding to the N-terminal sequence 4-14 
of human VLC-1 to aminohexylagarose in order to bind G-actin. 
We found, that G-actin specifically binds to the affinity beads. 
Furthermore, preincubation of G-actin with P5-14 of both ALC-
1 and VLC-1 decreased the amount of G-actin recovered from 
the affinity beads in a concentration-dependent manner. The 
half-maximal effective concentrations, however were signifi-
cantly (p < 0.01) different being 0.32 ± 0.02 μΜ and 0.71 ± 0.02 
μΜ for the VLC-1 and ALC-1 peptide, respectively. The 
appropriate scrambled peptides were without effect up to 3 
μΜ. These results demonstrate the specific interaction between 
the N-terminal domains of human cardiac MLC-1 isoforms and 
actin and reveal different actin affinities of MLC-1 isoforms. 
Weak binding of ALC-1 to actin could explain the higher cycling 
kinetics of cross-bridges with ALC-1 compared to those with 
VLC-1. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cardiac myosin molecule consists of two heavy chains 
(MHC; 200 kDa), each associated with two types of light 
chains (MLC) [1]. Two genes coding for MHC are expressed 
in the mammalian heart, namely the alpha-MHC and the 
beta-MHC located in tandem on chromosome 14 [2-4]. The 
MLC types are classified into essential MLC (MLC-1) and 
regulatory (phosphorylatable) MLC (MLC-2) [5,6]. Recent 
X-ray crystallographic analysis demonstrated that both essen-
tial and regulatory MLC are associated with the neck region 
of the myosin-Sl fragment [7]. Two MLC-1 isoforms are pro-
duced by two different genes, namely a ventricular-specific 
(VLC-1) which is the same isoform as the MLC-1 present in 
adult slow skeletal muscle, and an atrial-specific (ALC-1) iso-
form [8,9]. Human heart fibers with high ALC-l/VLC-1 ratio 
exhibited an increased shortening velocity (Vmax) as well as an 
accelerated rate of tension development [10], thus improving 
the contractile state of the heart. 
The molecular mechanism explaining the effects of essential 
MLC on the cross-bridges in the heart may reside in the mode 
of interaction between MLC-1 and actin. It has been demon-
corresponding author. Fax: (49) (30) 9406-2277. 
strated that the amino-terminal domain of MLC-1 isoforms 
interact with the carboxyl-terminal domain of actin [11-13]. 
This interaction could be of functional importance since in-
hibition of this interaction using synthetic peptides increased 
force production and shortening velocity of human heart fi-
bers [14] and myofibrillar ATPase [15]. We proposed that 
MLC-1-actin interaction imposes a 'molecular load' on the 
myosin cross-bridge. Relieving this load accelerates cross-
bridge cycling kinetics and may enhance tension output per 
cross-bridge thus increasing contractility. Interestingly, the 
primary structure of the most amino terminus of the ALC-1 
and VLC-1 are different [8]. We hypothesized that binding of 
ALC-1 to actin is weaker than binding of VLC-1 to actin thus 
decreasing the 'molecular load' imposed on the cross-bridge. 
This would, in analogy to weakening MLC-1-actin interaction 
by peptides, explain the accelerated cross-bridge cycling ki-
netics and tension production by ALC-1 expression in the 
human ventricle [10]. 
2. Material and methods 
2.1. Actin purification 
Actin was prepared from rabbit psoas [16] and was a generous gift 
from Dr. P. Allison, Heidelberg, Germany. Lyophilized actin (100 mg) 
was suspended in 3 ml actin buffer consisting of 5 mM HEPES, pH 
7.5, 1 mM ATP, 0.2 mM CaCl2, 0.5 mM NaN3 and was homogenized 
by a glass-teflon homogenizer. Following centrifugation at 200 000 X g 
for 1 h the supernatant was recovered as G-actin. The concentration 
was estimated by measurement of optical density at 290 nm: 0.63 = 1 
mg/ml). 
2.2. Synthetic peptide 
The N-terminal amino acid sequences 5-14 of VLC-1 (KPEPKKD-
DAK) and ALC-1 (KPEPKKEAAK) (human heart sequence) [8] as 
well as the corresponding scrambled peptides (PKDKEAKPKD for 
VLC-1 and PKEKEAKPKA for ALC-1) were commercially synthe-
sized and purified by BioTeZ (Berlin, Germany). The purity was 
greater than 98% as assessed by HPLC and mass spectroscopy. 
2.3. MLC affinity beads 
A synthetic peptide with the N-terminal sequence 4-14 
(KKPEPKKDDAK) of the VLC-1 was covalently coupled to an 
agarose gel. To achieve covalent coupling, the peptide was synthetized 
with a N-terminal monochloro-acetyl-glycyl extension. This peptide 
was then immobilized to activated w-aminohexylagarose via activation 
by 2-iminothiolane hydrochloride as described [17]. Coupling reaction 
was performed in phosphate-buffered saline (PBS, pH 7.4) for 3 h at 
room temperature and at a peptide concentration of 6 mg/ml packed 
gel. The peptide resin was then incubated for 1 h with 5 ml of 40 mM 
iodoacetamide to block the remaining active groups. The MLC affin-
ity bead was extensively washed with PBS and stored in the presence 
of 1% bovine serum albumine and 0.02% sodium azide. 
2.4. Actin binding to affinity beads 
MLC affinity beads (15 μΐ of packed gel) were incubated with 50 μg 
G-actin in a final volume of 500 μΐ actin buffer for 1 h at +4°C on a 
rotating wheel. Competition experiments were performed by incuba-
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tion of different concentrations of either ventricular MLC peptide 5-
14 or atrial MLC peptide 5-14 or the corresponding scrambled pep-
tides with G-actin for 12 h at +4°C prior binding to affinity beads for 
1 h at +4°C as outlined above. Following actin binding the beads were 
washed three times with actin buffer, extracted with 20 ml SDS-sam-
ple buffer (5% SDS, 50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 75 
mM urea, 60 mM ß-mercaptoethanol) and heated at 95°C for 2 min. 
The resulting supernatants were further processed by SDS-PAGE, 
while the affinity beads were discarded. 
2.5. SDS-PAGE and immunoblot analysis 
Samples were electrophoretically separated on 8% polyacrylamide 
gels at 4°C for 3 h and transferred to nitrocellulose (Hybond-C, 45 
μιη, Amersham, Germany) in a buffer containing 40 mM Tris, 300 
mM glycin, 0.01% SDS, 20% (v/v) methanol. Briefly, the blots were 
incubated with the monoclonal antibody against a-sarcomeric actin 
(Sigma, Munich, Germany) at a dilution of 1:500 for 90 min and the 
secondary peroxidase-conjugated antibody (anti-mouse IgG, Bio-
Genes, Germany, diluted 1:10000) for 1 h at room temperature. 
The 43-kDa actin band was visualized by enhanced chemolumines-
cence reaction kit (Amersham, Germany) using an X-ray film. 
2.6. Statistical analysis 
Statistical analysis was performed using the commercially available 
statistic program 'Instat2' on an IBM compatible PC (means, stand-
ard deviations (SD), Student's /-test for unpaired values). All values 
are expressed as means ± SEM. 
3. Results 
3.1. Binding of G-actin to affinity beads 
As demonstrated in Fig. 1, the synthetic peptide corre-
sponding to the N-terminal VLC-1 sequence 4-14 covalently 
linked to aminohexylagarose binds G-actin in a time-depend-
ent manner. At +4°C, maximal actin binding could be de-
tected after 1 h. Under the same experimental conditions, 
no G-actin binding was observed to the aminohexylagarose 
matrix alone (data not shown). 
3.2. Binding of N-terminal ALC-1 and VLC-1 peptides to 
G-actin 
To demonstrate that peptides derived from the N-terminal 
domains 5-14 (P5-14) of ALC-1 and VLC-1 bind to G-actin 
with different affinities, we incubated G-actin with different 
peptide concentrations for 12 h at +4°C prior incubation 
with the affinity beads. Different peptide affinities should pro-
duce different fractions of unbound G-actin concentrations 
which could subsequently be recovered from the affinity beads 
and detected by the actin antibody in the Western blot. 
Pre-incubation of G-actin with 1 μΜ of P5-14 of VLC-1 
saturated actin interaction sites preventing thereby subsequent 
binding to the affinity beads (Fig. 2. The corresponding VLC-
1 scrambled peptide (3 μΜ) did not bind to actin. Please note 
from the Western blots shown in Fig. 2, that the G-actin 
signal obtained after incubation with 3 μΜ scrambled peptide 
was about the same as that obtained upon G-actin binding 
alone (cf. gels Nos. 5 and 7 in Fig. 2A). These results suggest 
that binding of the N-terminal domain 5-14 of VLC-1 to actin 
is site-specific. Half-maximal effective dosage of the VLC-1 
peptide was 0.32±0.02 μΜ (6 different experiments; Fig. 2B). 
Likewise, the N-terminal ALC-1 sequence 5-14 removed G-
actin from the equilibrium reaction in a concentration-de-
pendent manner, while a corresponding scrambled peptide 
up to 3 μΜ was not effective (Fig. 2): Western blots (Fig. 
2A) show, that the G-actin signal obtained after incubation 
with 3 μΜ scrambled peptide was about the same as that 
obtained upon G-actin binding alone (cf. gels Nos. 5 and 6 
Fig. 1. (A) Time-dependent binding of G-actin to affinity beads as 
revealed upon elution and Western blot (ECL signal). A peptide 
corresponding to the human VLC-1 sequence 4-14 was covalently 
coupled to aminohexylagarose to bind G-actin. a, b, c and d corre-
spond to the signals obtained after 10 min, 30 min, 60 min and 120 
min, respectively. (B) ECL signals obtained from (A) (optical den-
sities OD in arbitrary units) were plotted versus incubation time of 
affinity beads with G-actin. 
in Fig. 2A). However, binding of the ALC-1 peptide to G-
actin was significantly weaker than binding of the VLC-1 
peptide. Even at 3 μΜ ALC-1 peptide, a considerable amount 
of G-actin could be eluted from the affinity beads. Half-max-
imal effective concentration of the ALC-1 peptide was found 
to be 0.71 ±0.02 (Fig. 2B) and was significantly O?<0.01) 
higher than different from the VLC-1 peptide. 
4. Discussion 
We developed an in vitro actin binding assay using amino-
hexylagarose covalently coupled with a synthetic peptide cor-
responding to the N-terminal actin binding domain 4-14 of 
VLC-1 [8]. G-actin was pre-incubated with free ALC-1 or 
VLC-1 peptides (or the corresponding scrambled peptides) 
to obtain equilibrium between bound and free actin. The equi-
librium complex is than incubated with the affinity beads 
which bind the free G-actin. The prediction was that in the 
equilibrium reaction with low affinity peptides a higher frac-
tion of free G-actin exist which can be recovered by subse-
quent incubation with the affinity beads. 
We could demonstrate that G-actin binds to affinity beads. 
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Fig. 2. (B) Recovery of G-actin from affinity beads (ECL signals). G-actin was incubated with different concentrations (in mol/1) of synthetic 
peptides corresponding to the N-terminal domains of 5-14 (P5-14) of the atrial and ventricular myosin light chain 1 (ALC-1 and VLC-1, re-
spectively) of the human heart. 1, 2, 3 and 4, correspond to 3 μΜ, 1 μΜ, 0.3 μΜ and Ο.ΙμΜ peptide, respectively; 5 corresponds to actin 
alone; 6 and 7 correspond to 3 μΜ ALC-1 and VLC-1 scrambled peptide, respectively. (B) Plot of G-actin recovered from the affinity beads 
(given in % of maximal ECL signal obtained without competing peptide) versus different concentrations of ALC-1 (closed circles) and VLC-1 
(closed squares) peptides corresponding to the N-terminal domain 5-14 (P5-14) of the human heart. 
This shows for the first time that the N-terminal sequence 4— 
14 of human cardiac VLC-1 indeed interacts with actin as 
recently demonstrated for skeletal muscle MLC-1 [11-13]. 
Pre-incubation of G-actin with the N-terminal peptide 5-14 
of VLC-1 prevented actin from binding to the affinity beads at 
a peptide concentration of around 1 μΜ. The corresponding 
scrambled peptide at the same concentration was without ef-
fect demonstrating that the binding of the N-terminal MLC-1 
peptides is highly specific. The main finding in this paper is 
that the actin affinity of the N-terminal peptides 5-14 derived 
from ALC-1 and VLC-1 was different: in our assay system, 
half-maximal effective dosage of P5-14 of VLC-1 was 0.32 μΜ 
while half-maximal effective dosage of P5-14 of ALC-1 was 
0.71 μΜ. From our data it appears that amino acids 7 and 8 
of MLC-1 regulate the affinity of the N terminus of MLC-1 to 
actin. This supports our initial hypothesis: the increased 
cross-bridge cycling kinetics in the presence of ALC-1 is due 
to a weak actin-binding of its N terminus. Thus, ALC-1 
would impose a weaker 'molecular load' to the cross-bridge 
than VLC-1 increasing its kinetic and force generation. Fur-
thermore, reconstitution of skinned skeletal muscle fibers with 
those MLC-1, in which charged amino acids were substituted 
by uncharged alanine at the most N terminus increased short-
ening velocity [18]. Please note, that the first 20 N-terminal 
amino acids of ALC-1 contains 7 charged amino acids while 
VLC-1 contains 9 charged amino acids within the first 20 N-
terminal amino acids in the human heart [8]. Decreasing the 
amount of charged amino acid residues - by mutation or 
differential MLC-1 isoform expression - increases cross-bridge 
cycling kinetics. 
In summary, the presented data support our hypothesis that 
the weak interaction between the N-terminal domains of 
ALC-1 with actin promotes cross-bridge cycling kinetics and 
force per cross-bridge thus improving the contractile state of 
the human heart. 
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